Apr. 13 at 7:01 PM
$ABCL Bottom line :
ABCL is the single strongest 10-bagger candidate that survived all screening filters: Investor52 criteria match
(92/100), minimal dilution history (5% over 3 years), ~4.3 years of self-funding cash runway, massive short interest for
squeeze mechanics (21.5% of float, 15.8 days to cover), defined binary catalysts in Q3-Q4 2026, and institutional
accumulation by sophisticated biotech investors. The enterprise value of ~
$500M for a platform that took
$1B+ and
15 years to build, with
$700M in liquidity and 19 molecules in clinic, represents a deeply asymmetric risk/reward at
current levels. The primary risk remains binary clinical outcomes
